Ignite Creation Date:
2025-12-24 @ 7:12 PM
Ignite Modification Date:
2025-12-28 @ 4:35 PM
Study NCT ID:
NCT02803203
Status:
COMPLETED
Last Update Posted:
2023-09-22
First Post:
2016-06-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-29
Start Date Type:
ACTUAL
Primary Completion Date:
2022-03-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-03-01
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-14
First Submit QC Date:
None
Study First Post Date:
2016-06-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-02-28
Results First Submit QC Date:
None
Results First Post Date:
2023-09-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-29
Last Update Post Date:
2023-09-22
Last Update Post Date Type:
ACTUAL